Effect of losartan on NOX2 transcription following acute myocardial ischemia-reperfusion

Physiology and Pharmacology

Volumn 16, Issue 1, 2012, Pages 44-53

  Safari, Fatemeh ^a,b   Hajizadeh, Sohrab ^a,c   Moshtaghion, Seyed Hosein ^b   Moghadam, Mahdi Forouzandeh ^a   Shekarforoush, Shahnaz ^d   Bayat, Gholamreza ^a   Mazlum, Roham ^a   Sattarian, Leila ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE FOR COGNITIVE SCIENCE STUDIES ICSS   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Losartan; Myocardial ischemia reperfusion; NOX2 mRNA

Indexed keywords

LOSARTAN; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY;

EID: 84922685263     PISSN: 17350581     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bedard K, Krause KH, The NOX family of ROSgenerating NADPH oxidases. Physiology and pathophysiology. Physiol Rev 87(2007) 245-313.
2. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM, Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105 (2002) 293-6.
3. Brandes RP, Weissmann N, Schrö der K, NADPH oxidases in cardiovascular disease. Free Radic Biol Med 49 (2010) 687-706.
4. Brann DW, Raz L, Zhang QG, Zhou CF, Han D, Gulati P, Yang LC, Yang F, Wang RM. Role of Rac1 GTPase in NADPH oxidase activation and cognitive impairment following cerebral ischemia in the rat. PLoS One 2010; 5(9): 12606.
5. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93(2003) 802-5.
6. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2699 (2000) 713-17.
7. Fortuño A, Bidegain J, Robador PA, Hermida J, López-Sagaseta J, Beloqui O, Díez J, Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension 54(2009) 744-50.
8. Hoffmeyer MR, Jones SP, Ross CR, Sharp B, Grisham MB, Laroux FS, Stalker TJ, Scalia R, Lefer DJ. Myocardial ischemia/reperfusion injury in NADPH oxidase-deficient mice. Circ Res 27 (2000) 812-7.
9. Krijnen PA, Meischl C, Hack CE, Meijer CJ, Visser CA, Roos D, Niessen HW. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 56 (2003) 194-9.
10. Katsuyama M. NOX/NADPH oxidase, the superoxidegenerating enzyme: its transcriptional regulation and physiological roles. J Pharmacol Sci 114(2010) 134-46.
11. Landmesser U, Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, Sorrentino S, Manes C, Schieffer B, Drexler H. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 100 (2007) 894-903.
12. Li JM, Shah AM, Mechanism of endothelial cell NADPH oxidase activation by angiotensin II, Role of the p47phox subunit. J Biol Chem 278(2003) 12094-100.
13. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res 909 (2002) 143-50.
14. Li J M, Gall N P, Grieve D J, Chen M, Shah A M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40 (2002) 477-84.
15. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51(2008) 319-25.
16. Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, Vázquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) 12 (2010) 7-21.
17. Polizio AH, Balestrasse KB, Gornalusse GG, Gorzalczany SB, Santa-Cruz DM, Yannarelli GG, Peña C, Tomaro ML. Losartan exerts renoprotection through NAD (P) H oxidase downregulation in a renovascular model of hypertension. Regul Pept 7 (2009) 28-33.
18. Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology insights from transgenic and knockout mouse models. Redox Rep 15 (2010) 50-63.
19. Safari F, Hajizadeh S, Shekarforoush S, Bayat G, Foadoddini M, Khoshbaten A. Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts. JRAAS, Article in press.
20. Safari F, Hajizadeh S, Shekarforoush S, Forouzandeh M, Bayat G, Foadoddini M, Khoshbaten A. Effects of pretreatment with non hypotensive dose of ramiprilat and losartan on myocardial ischemia-reperfusion induced arrhythmias and infarct size in rats. Physiol and Pharmacol 15 (2011) 116-23.
21. Samsamshariat SA, Samsamshariat ZA, Movahed MR. A novel method for safe and accurate left anterior descending coronary artery ligation for research in rats. Cardiovasc Revasc Med 6 (2005) 121-3.
22. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR, NADPH oxidases in the vasculature molecular features roles in disease and pharmacological inhibition. 120 (2008) 254-91.
23. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 44(2005) 797-814.
24. Sladek T, Sladkova J, Kolar F, The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovas Res 31 (1996) 568-76.
25. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Expression of a functionally active gp91phoxcontaining neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries regulation by angiotensin II. Circ Res 90 (2002) 1205-13.
26. Unger T, Targeting cardiovascular protection: the concept of dual Renin-Angiotensin system control. Medscape J Med 10 (2008) S4.
27. Wan LL, Xia J, Ye D, Liu J, Chen J, Wang G. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit. Cardiovasc Ther 27 (2009) 28-33.
28. Wenzel P, Schulz E, Münzel T. Protein kinase Cinhibiting properties of the losartan metabolite EXP3179 make the difference. Hypertension 54 (2009) 707-9.
29. Yuan JS, Reed A, Chen F, Stewart CN Jr, Statistical analysis of real-time PCR data. Bioinformatics 22 (2006) 7-85.
30. Zaman MA, Oparil S, Calhoun DA: Drugs targeting the rennin-angiotensin-aldosterone system. Nature 1 (2002) 621-63039-6.
31. Zhao W, Zhao D, Yan R, Sun Y. Cardiac oxidative stress and remodeling following infarction. role of NADPH oxidase. Cardiovasc Pathol 25 (2008) 511-16.
32. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG IIinduced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 291 (2006): H336-43.
33. Zhu BQ, Sun YP, Sievers RE, Browne A, Lee R, Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. JRAAS 2 (2001) 129-33.